COMP <GO>
EBS vs ABBV // EV/EBITDA & P/E VALUATION
Emergent BioSolutions Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: EBS 4
— ABBV 8
▲ EV/EBITDA & P/E VALUATION LEADER: EBS
LAST: $7.22 (+1.83%) • MKT CAP: $370.2M
valuation
6.6x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EBS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.10% | 70.20% | -14.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 29.00% | -20.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.6x | 33.3x | -26.70 | EBS | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 13.50% | 24.60% | -11.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.10% | 6.90% | +0.20 | EBS | /net-margins <GO> |
| Revenue Growth (YoY) | -28.80% | 8.60% | -37.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.41 | 5.33 | -3.92 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | EBS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 65.1 | -12.12 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 113.1x | -106.60 | EBS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $370.2M | $513.86B | -$513.49B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EBS REV | ABBV REV | EBS GROSS % | ABBV GROSS % | EBS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $61.16B | 56.1% | 70.2% | $156.8M | $17.82B |
| FY 2024 | $1.04B | $56.33B | 34.7% | 70.0% | $35.8M | $17.83B |
| FY 2023 | $1.05B | $54.32B | — | — | -$206.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
ABBV // BETA 1.15